Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Is now a reality
| The first 150 words of the full text of this article appear below. |
Heparin therapy for at least five days followed by long term oral anticoagulation has been the standard care for patients with acute deep vein thrombosis.1 Initiation of treatment usually requires patients to be admitted to hospital for administration of intravenous unfractionated heparin and dose adjustment according to the results of the activated partial thromboplastin time. However, the emergence of low molecular weight heparin as a safe, effective, and convenient treatment for deep vein thrombosis has challenged the need for routine admission. A paper in this week's issue adds to the evidence that home treatment of deep vein thrombosis is now routinely feasible (p 1212).2
Aggregate data from a recent meta-analysis of randomised
trials,3 also summarised in a Cochrane systematic
review,4 show that low molecular weight heparin is at
least as effective and safe as unfractionated heparin for the initial
treatment of deep vein thrombosis. Unlike unfractionated heparin, which
is
Read all Rapid Responses